Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Approach for modulating regulatory t cells and inhibiting tumor growth

A regulatory, tumor technology, applied in chemical instruments and methods, anti-tumor drugs, anti-growth factor immunoglobulins, etc., can solve problems such as hindering the application of Treg targeting methods and limiting the therapeutic potential of Treg targeting methods.

Pending Publication Date: 2021-04-23
UNIVERSITY OF LAUSANNE
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although strategies to deplete Tregs increase antitumor responses, severe autoimmunity due to systemic loss of Tregs and unnecessary depletion of effector T cells limits the therapeutic potential of Treg-targeted approaches
In addition, the systemic impairment of suppressive function in Tregs by treatments targeting immune checkpoints expressed in Tregs (such as OX40, GITR, and CTLA-4) also hampers the application of Treg-targeted approaches in cancer therapy (Nishikawa, H .&Sakaguchi,S.International journal of cancer 127,759-767(2010);Simpson,T.R.et al.J Exp Med 210,1695-1710(2013);Curtin,J.F.et al.PLoS One 3,e1983(2008))
To date, finding effective targeting methods to selectively destroy intratumoral Tregs remains a challenge for cancer immunotherapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Approach for modulating regulatory t cells and inhibiting tumor growth
  • Approach for modulating regulatory t cells and inhibiting tumor growth
  • Approach for modulating regulatory t cells and inhibiting tumor growth

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0099] Example 1: This example describes the materials and methods to be used in subsequent examples.

[0100] mice. C57BL / 6 / J, FoxP3 YFP-Cre , Rag1 – / – (B6.129S7-Rag1 tm1Mom / J) Mice were purchased from Jackson Laboratories. CD36fl / fl mice were generated as previously described (Son, N.H. et al. J Clin Invest 128, 4329-4342 (2018).). PPARγ was produced as described by Dammone, G et al. fl / fl and PPARβ fl / fl Mice (Dammone, G. et al. International journal of molecular sciences 19 (2018)). Dankort et al. (Dankort et al. Nature Genetics volume 41, pages 544-552 (2009)) describe BRafCA; Tyr::CreER; Ptenlox4-5 (Braf / Pten). K-ras in NSCLC is described by DuPage et al. (DuPage et al. Nature Protocols Vol. IV, pp. 1064–1072 (2009)) LSL-G12D / + / p53 fl / fl Conditioned mouse model. Animals were maintained at the Specific Pathogen Free Facility of the University of Lausanne and all experimental studies were approved and performed in accordance with the guidelines and regulations ...

Embodiment 2

[0116] Example 2: Intratumoral Treg increases lipid metabolism and CD36 expression

[0117] To elucidate whether intratumoral Tregs preferentially participate in specific metabolic pathways, in a previously published study, RNA sequencing results of intratumoral Tregs and circulating Tregs obtained from breast cancer patients were first analyzed (Plitas, G. et al. Immunity 45, 1122 -1134). Gene pathway analysis, with a particular focus on metabolic pathways, revealed that intratumoral Tregs highly expressed metabolic genes responsible for lipid metabolism compared with circulating Tregs ( Figure 1a and 1b), suggesting that intratumoral Tregs may increase their lipid metabolism. Indeed, a comparison between peripheral blood mononuclear cells (PBMCs) from patients with non-small cell lung cancer (NSCLC) and intratumoral Tregs revealed that intratumoral Tregs internalized higher amounts of the green fluorescent fatty acid, Bodipy FL C12, and contained Higher neutral lipid cont...

Embodiment 3

[0118] Example 3: CD36 controls the accumulation of Treg in the tumor and inhibits its function

[0119] To investigate whether CD36 expression regulates Treg behavior in tumors, CD36 fl / fl mice with Foxp3 YFP-Cre Mice were crossed to generate Treg-specific CD36-deficient mice (termed Treg CD36- / - ). Given that genetic ablation of key regulators in Tregs could lead to systemic activation of T lymphocytes and autoimmunity due to impairment of Treg suppressive function, we first examined whether CD36 deficiency in Tregs affects immune homeostasis. found that in both sexes, older Treg CD36- / - Mice (21-23 weeks) showed a strong association with Foxp3 YFP-Cre Mice (referred to as wild-type mice throughout the study) were of comparable body weight. Compared with WT mice, Treg CD36- / - CD4 + and CD8 + A similar proportion of effector or memory populations (CD44 hi CD62L lo ). In addition, Treg CD36- / - Mice showed neither abnormal infiltration of lymphocytes and myeloid cel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
Login to View More

Abstract

Provided herein is approach that specifically modulates the activity and / or the number of intratumoral regulatory T (Treg) cells in a subject. Such an approach can be used to reduce the number of intratumoral T regulatory cells in a subject as well as to inhibit tumor growth in a subject having a cancer without eliciting autoimmune responses. The approach relies on the inhibition of CD36 or of PPARbeta.

Description

[0001] Cross References to Related Applications [0002] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 62 / 731,351, filed September 14, 2018. The entire contents of the aforementioned applications are incorporated herein by reference. [0003] field of invention [0004] The present invention relates to a method for regulating intratumoral regulatory T (Treg) cells and inhibiting tumor growth in a subject, more particularly to regulating intratumoral Treg cells and inhibiting tumor growth in a subject by a CD36 inhibitor or a PPARβ inhibitor method of growth. [0005] Background of the invention [0006] Regulatory T (Treg) cells are a unique T cell population that regulate the immune system, maintain tolerance to self-antigens, suppress abnormal activation of autoreactive T cells, and eliminate autoimmune diseases. Treg cells mediate their regulatory functions through multiple mechanisms. First, Treg cells express anti-i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P35/00C07K16/22C07K16/28A61K39/00
CPCC07K16/2896C07K16/22C07K2317/73C07K2317/76A61K2039/505A61P35/00A61K39/001129A61K31/18A61K31/381A61K31/437A61K31/44A61K31/5377A61K38/08A61K39/3955C07K16/2818
Inventor P-C.何H.王
Owner UNIVERSITY OF LAUSANNE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com